Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis

被引：1
|
作者：
Blauvelt, A. [1 ]
Langley, R. [2 ]
Leonardi, C. [3 ]
Gordon, K. [4 ]
Luger, T. [5 ]
Ohtsuki, M. [6 ]
Nickoloff, B. [7 ]
Kerr, L. [7 ]
Mallbris, L. [7 ]
Reich, K. [8 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Dalhousie Univ, Halifax, NS, Canada
[3] St Louis Univ, St Louis, MO 63103 USA
[4] Northwestern Univ, Feinberg Sch Med, St Louis, MO USA
[5] Univ Munster, Munster, Germany
[6] Jichi Med Univ, Shimotsuke, Japan
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
[8] Dermatologikum Hamburg & SCIderm Res Inst, Hamburg, Germany
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 09期
关键词：
D O I：
10.1016/j.jid.2016.06.408
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
388
引用
收藏
页码：S227 / S227
页数：1
相关论文
共 50 条
  • [31] Correlations between etiopathogenic factors and persistence of anti-IL-17A biologic therapies in patients with severe psoriasis vulgaris
    Bucur, S.
    Ciurduc, M.
    Savu, A.
    Mutu, C.
    Serban, E. D.
    Cuciumita, A.
    Olteanu, R.
    Madan, V.
    Constantin, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S208 - S208
  • [32] Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study
    Blauvelt, Andrew
    Shi, Nianwen
    Murage, Mwangi J.
    Ridenour, Terri Lynn
    Lew, Carolyn R.
    Somani, Najwa
    Zhu, Baojin
    Zimmerman, Nicole M.
    Kern, Scott A.
    Burge, Russel T.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2022, 21 (04) : 399 - 407
  • [33] Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis
    Reich, K.
    Blauvelt, A.
    Armstrong, A.
    Langley, R. G.
    Fox, T.
    Huang, J.
    Papavassilis, C.
    Liang, E.
    Lloyd, P.
    Bruin, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (03) : 752 - 758
  • [34] Long-term Safety of Ixekizumab in Adult Patients With Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis
    Deodhar, Atul
    Blauvelt, Andrew
    Schwartzman, Sergio
    Salvarani, Carlo
    Feely, Meghan
    Kronbergs, Andris
    Eberhart, Nadia
    Zhu, Danting
    Mevel, Elsa
    Holzkaemper, Thorsten
    Krishnan, Eswar
    Lebwohl, Mark
    Rahman, Proton
    Marzo-Ortega, Helena
    JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 39 - 40
  • [35] LONG-TERM SAFETY OF IXEKIZUMAB IN ADULT PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS
    Deodhar, Atul
    Blauvelt, Andrew
    Schwartzman, Sergio
    Salvarani, Carlo
    Feely, Meghan
    Kronbergs, Andris
    Eberhart, Nadia
    Zhu, Danting
    Mevel, Elsa
    Holzkaemper, Thorsten
    Krishnan, Eswar
    Lebwohl, Mark
    Rahman, Proton
    Marzo-Ortega, Helena
    Nash, Peter
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 37 - 37
  • [36] LONG-TERM SAFETYOF IXEKIZUMAB IN ADULT PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS
    Deodhar, Atul
    Blauvelt, Andrew
    Schwartzman, Sergio
    Salvarani, Carlo
    Feely, Meghan
    Kronbergs, Andris
    Rahman, Proton
    Marzo-Ortega, Helena
    de Lima Tostes, Camila
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 : S99 - S99
  • [37] Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis
    Deodhar, Atul
    Blauvelt, Andrew
    Schwartzman, Sergio
    Salvarani, Carlo
    Feely, Meghan
    Kronbergs, Andris
    Eberhart, Nadia
    Zhu, Danting
    Mevel, Elsa
    Holzkamper, Thorsten
    Krishnan, Eswar
    Lebwohl, Mark
    Rahman, Proton
    Marzo-Ortega, Helena
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2071 - 2074
  • [38] LONG-TERM SAFETY OF IXEKIZUMAB IN ADULT PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS
    Deodhar, Atul
    Blauvelt, Andrew
    Schwartzman, Sergio
    Salvarani, Carlo
    Feely, Meghan
    Kronbergs, Andris
    Eberhart, Nadia
    Zhu, Danting
    Mevel, Elsa
    Holzkaemper, Thorsten
    Krishnan, Eswar
    Lebwohl, Mark
    Rahman, Proton
    Marzo-Ortega, Helena
    Bullock, Craig
    RHEUMATOLOGY, 2023, 62
  • [39] Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study
    Genovese, Mark C.
    Carlier, Hilde
    Erickson, Janelle
    Braun, Daniel
    Banerjee, Subhashis
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S188 - S188
  • [40] IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment
    Mercurio, Laura
    Morelli, Martina
    Scarponi, Claudia
    Eisenmesser, Elan Z.
    Doti, Nunzianna
    Pagnanelli, Gianluca
    Gubinelli, Emanuela
    Mazzanti, Cinzia
    Cavani, Andrea
    Ruvo, Menotti
    Dinarello, Charles A.
    Albanesi, Cristina
    Madonna, Stefania
    CELL DEATH & DISEASE, 2018, 9
12345